A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

Summary

GSK2798745 is a potent and selective transient receptor potential vanilloid 4 (TRPV4) channel blocker being investigated for the treatment of chronic cough. This is a multi-center, randomized, placebo-controlled, double-blind, two-period crossover study with a purpose to evaluate efficacy and safety of GSK2798745. Each subject will have 2 treatment periods, and will be randomized to one of the following treatments in each period: A) Placebo matching to GSK2798745 once daily for 7 days. B) 4.8 milligrams (mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 once daily for 6 days. There will be a washout period of 14 to 21 days between the treatment periods. A maximum of 48 subjects will be enrolled in the study and the total duration of participation in the study will be maximum of 10 and a half weeks including follow-up visit.

Timeline

Start

2018-04-05

Primary completion

2018-10-08

Completion

2018-10-08

Outcome

Outcome not reported

Stopped: “Study terminated due to lack of efficacy of GSK2798745 in chronic cough.”

Drugs

Indications

No indication recorded.